ERBB2 and breast carcinoma: CDK4/6i combined with endocrine therapy has demonstrated PFS and OS benefit for HR-positive and HER2-negative advanced breast cancer, as confirmed by the PALOMA, MONALEESA, and MONARCH trials [1,2,3,4,5].